Thermo Fisher Scientific (TMO) vs. Danaher (DHR) — A Thorough Comparison of Business Growth Potential

[Two Giants Selling Science — How to Interpret the 'Goodwill' of Companies Built Through Acquisitions]

Record Date: July 28, 2026

As of the stock price record date: Danaher (hereinafter Danaher) is based on the U.S. market closing price on July 27, 2026, and Thermo Fisher Scientific (hereinafter Thermo Fisher) is based on data as of July 24, 2026.There is a one-business-day difference.

The fiscal year-end is the same: Both companies have a December fiscal year-end and report under US GAAP. Furthermore, both companies announced their Q2 2026 results within the last week (Danaher on July 21, 2026, and Thermo Fisher on July 23, 2026). They are in a state that is easy to compare.

Currency: Amounts are generally stated in U.S. dollars. Yen conversions are reference values, calculated at 1 dollar = 163.6 yen (based on the closing price of the New York foreign exchange market on July 24, 2026).

Regarding exchange rate risk: When purchasing U.S. stocks in yen, fluctuations in the dollar-yen exchange rate directly affect yen-denominated gains and losses in addition to stock price movements. Even if the valuation in dollars does not change, if the yen strengthens, the yen-denominated valuation will decrease.

Danaher's stock price plummeted after earnings (Important): Following the Q2 earnings announcement on July 21, 2026, Danaher stock fell as much as 14.3% that day, selling down to $172.29.The scale of the decline is reported to be the largest in decades. This was due to concerns over the timing of shipments in the bioprocessing business and the core revenue outlook, despite profit growth and raised guidance. It has since recovered, with the July 27 closing price at $196.50. The stock price in this article is at this recovered level.

Both companies have significantly different figures between GAAP and non-GAAP (adjusted): Because adjusted items include the amortization of intangible assets associated with acquisitions, there is a large difference between GAAP profit and adjusted profit. This article specifies both.

Changes in business portfolio: Thermo Fisher announced the sale of its microbiology business in Q2 and expects to complete it during Q3. Danaher completed the acquisition of Masimo earlier than planned in Q2.

The Author's Focus Points

• Attention Level: Thermo Fisher Scientific ★★★★☆ / Danaher ★★★☆☆

The author has a somewhat stronger interest in Thermo Fisher. Q2 organic growth of 5%, adjusted EPS growth of 13%, adjusted operating margin improvement of 90 basis points, and an increase in full-year guidance.All the numbers are pointing in the same direction.

However, Danaher exceeds Thermo Fisher in profitability itself, with a gross margin of 58.99% and an operating margin of 22.00%. Its D/E ratio is also lighter at 0.37 vs. 0.81.It is a pair where opinions are divided, including the fact that the stock price just plummeted.

① Comparison of Current Stock Price and Valuation

Thermo Fisher Scientific (TMO/NYSE)

• Stock Price: Approx. $568.27 (as of July 24, 2026, calculated by market capitalization ÷ shares outstanding / approx. 92,970 yen)

• Market Capitalization: Approx. $211.18 billion (approx. 34.5 trillion yen) / Enterprise Value (EV): Approx. $249.66 billion

• Shares Outstanding: Approx. 371.62 million shares (a 1.45% decrease in one year)

• P/E (TTM): approx. 30.58x / Fwd P/E: approx. 21.66x / PEG Ratio: 2.53

• EV/EBITDA: 24.31x / EV/FCF: 34.12x

• Dividend: $1.88 per year, dividend yield approx. 0.33%

• Beta: 0.87 / 52-week range: $435.27–$643.99

• Stock price change over the last 52 weeks: approx. +21.76%

• Gross margin 40.91% / Operating margin 18.98% / Net margin 15.04%

• ROE: 13.52% / ROIC: 8.84% / D/E Ratio: 0.81 / Current Ratio: 1.55

• Net debt: approx. $38.49 billion (cash $4.06 billion, debt $42.55 billion)

• Operating cash flow (TTM): $9.01 billion / Free cash flow: $7.32 billion

• Number of employees: approx. 125,000 / Fiscal year-end: December

Danaher (DHR/NYSE)

• Stock price: $196.50 (closing price on July 27, 2026, +2.61% from previous day / approx. 32,150 yen)

• Market cap: approx. $138.14 billion (approx. 22.6 trillion yen) / Enterprise Value (EV): approx. $150.73 billion

• Shares outstanding: approx. 702.99 million shares (2.27% decrease in one year)

• P/E (TTM): approx. 34.11x / Fwd P/E: approx. 21.62x / PEG Ratio: 2.59

• EV/EBITDA: 19.00x / EV/FCF: 28.49x

• Dividend: $1.60 per year, dividend yield approx. 0.81%

• Beta: 0.82 / 52-week range: $160.93–$242.80

• Stock price change over the last 52 weeks: approx. -2.16%

• Revenue (TTM): approx. $25.11 billion (up 4.6% year-on-year) / Net income (TTM): approx. $4.00 billion (up 17.3% year-on-year)

• Gross Margin 58.99% / Operating Margin 22.00% / Net Margin 14.89%

• ROE: 7.08% / ROIC: 6.86% / D/E Ratio: 0.37 / Current Ratio: 1.87

• Net Debt: Approx. $13.98 billion ($5.70 billion in cash, $19.68 billion in debt)

• Operating Cash Flow (TTM): $6.44 billion / Free Cash Flow: $5.29 billion

• Number of Employees: 60,000 / Fiscal Year-End: December

What the Comparison Reveals

The Fwd P/E ratios are almost identical at 21.66x vs. 21.62x. The market is valuing both companies at nearly the same price relative to their earnings over the next year.

Despite this, the underlying metrics are polar opposites.

• Gross Margin: Danaher 58.99% vs. Thermo Fisher 40.91% — Danaher is 18 points higher

• Operating Margin: Danaher 22.00% vs. Thermo Fisher 18.98% — Danaher is 3 points higher

• ROE: Thermo Fisher 13.52% vs. Danaher 7.08% — Thermo Fisher is about double

• ROIC: Thermo Fisher 8.84% vs. Danaher 6.86%

Danaher, which leads in profit margins, significantly lags in capital efficiency. This reversal is the key to understanding this pair (we will cover this in detail in section 8).

Financially, Danaher clearly has a lighter structure. The D/E ratio is 0.37 vs. 0.81, and net debt is $13.98 billion vs. $38.49 billion. The EV/EBITDA is also 19.00x vs. 24.31x, meaning Danaher has a lower multiple on an enterprise value basis, including debt.

② Comparison of Recent Financial Results

Thermo Fisher Scientific: Q2 Fiscal Year 2026 (Announced July 23, 2026, ended June 27)

• Revenue: $11.99 billion (10% increase from $10.55 billion in the same period last year)

• Organic Revenue Growth: 5%

• GAAP Operating Income: $2.09 billion

• GAAP Diluted EPS: $4.68 (9% increase)

• Adjusted Operating Income: $2.73 billion (up 15%)

• Adjusted Operating Margin: 22.8% (90 basis point improvement from 21.9% in the same period last year)

• Adjusted EPS: $6.03 (up 13%) — exceeded market expectations of $5.72 by $0.31

• Share Repurchases: $1 billion

By end market, the largest market, Pharmaceutical and Biotechnology, saw mid-single-digit growth, led by bioproduction, clinical research, and research & safety market channels. Academic and Government grew in the low-single digits, driven by chromatography and mass spectrometry. Industrial and Applied saw mid-single-digit growth.

Announced the divestiture of the microbiology business, which is expected to be completed during the third quarter. This divestiture is expected to reduce 2026 revenue by approximately $200 million (net of remaining sales channel business) and adjusted EPS by $0.05. The company utilized the expected proceeds from the divestiture to conduct $1 billion in share repurchases in the second quarter.

Full Year 2026 Outlook (Upward Revision)

• Revenue: $47.4 billion to $48.1 billion (up 6–8% year-over-year)

• Organic Revenue Growth: Approximately 4% (the upper end of the previous 3–4% range)

• Adjusted EPS: $24.93 to $25.33 (up 9–11% year-over-year, a $0.25 increase at the midpoint)

Danaher: Second Quarter 2026 (Announced July 21, 2026)

*All figures below are on a continuing operations basis.

• Revenue: $6.27 billion (up 5.5% year-over-year)

• Non-GAAP Core Revenue Growth: 3.0% (on a basis excluding respiratory testing, 4.5%, accelerating from 3.0% in the first quarter)

• Net Income: $870 million, diluted EPS $1.23 (up 60%)

• Non-GAAP Adjusted Diluted EPS: $1.94 (up 8.0%) — exceeded market expectations of $1.84

• Operating Cash Flow: $1.5 billion / Non-GAAP Free Cash Flow: $1.3 billion

The decline in respiratory testing created a 1.5-point headwind to total company core growth. The company expects this headwind to strengthen to approximately 2.5 points in the third quarter and to ease in the fourth quarter as the comparison base softens.

The Life Sciences segment had its strongest quarter in several years. Meanwhile, Bioprocessing revenue was impacted by the timing of customer projects. However, order trends remain solid, with Bioprocessing orders growing in the mid-teens during the quarter.

Completed the acquisition of Masimo earlier than expected, and also mentioned the acquisition of StatLab.

Full-year 2026 outlook

• Non-GAAP core revenue growth: 3.0–4.0% (unchanged). Expected to reach mid-single digits excluding respiratory testing

• Adjusted diluted EPS: $8.45–$8.60 (raised from the previous $8.35–$8.55) — equivalent to an annual earnings increase of approximately 10% at the midpoint

• Q3 core revenue growth: 2.0–3.0%

• The company has indicated an expectation to reach mid-single-digit core growth rates by the end of 2026

Fiscal Year 2025 (Actual): Revenue of $24.57 billion (up 2.90% YoY), net income of $3.61 billion (down 7.31% YoY).

What the comparison reveals

5% vs. 3.0% in organic (core) growth. Thermo Fisher outperforms even when compared to Danaher's 4.5% excluding respiratory testing.

Adjusted EPS growth is also 13% vs. 8.0%. Thermo Fisher saw a 90-basis-point improvement in adjusted operating margin, whereas Danaher experienced slight margin compression.

And the market reaction was decisively different. Despite earnings growth and raised guidance, Danaher fell as much as 14.3% and was sold down to 52-week lows due to concerns over bioprocessing shipment timing. Thermo Fisher clearly beat market expectations and raised its full-year outlook.

③ Comparison of Business Structure and Mid-term Plans

Thermo Fisher Scientific's Business Structure

A company with over $45 billion in annual revenue that positions itself as the "world leader in serving science." It is composed of four business segments.

Main business areas and brands

• Thermo Scientific — Analytical instruments, mass spectrometry, and chromatography

• Applied Biosystems — Genetic analysis and PCR-related products

• Invitrogen, Gibco — Life science reagents and cell culture media

• Fisher Scientific — Sales channel for research materials

• Contract Development and Manufacturing Organization (CDMO) and clinical research services

Strengths

• Scale of sales channels: With the Fisher Scientific purchasing platform for researchers, they can deliver equipment, reagents, and consumables in bulk. This is a strength that secures a 'gateway' for laboratories.

• PPI Business System: A company-wide operational improvement methodology. They have increased profitability by rolling this out to acquired companies.

• ROE of 13.52% and ROIC of 8.84%, representing high capital efficiency between the two companies

• TTM free cash flow generation capacity of $7.32 billion

• The stock price has risen approximately 21.76% over the last 52 weeks. Market evaluation is on a recovery trend.

Challenges

• The gross margin of 40.91% is 18 points lower than Danaher's. This is due to a structure that includes lower-margin businesses such as sales channels and CDMO.

• D/E ratio of 0.81 and net interest-bearing debt of $38.49 billion. Debt has accumulated as a result of repeated acquisitions.

• Dividend yield of 0.33%, indicating limited returns.

• EV/EBITDA of 24.31x, which is a higher valuation level than Danaher's.

Mid-term policy: They advocate a 'proven growth strategy' that combines organic growth with acquisitions, while simultaneously improving profitability through the PPI Business System. They are also proceeding with portfolio replacement, combining the divestiture of the microbiology business with share buybacks. The management team is led by Chairman and CEO Marc N. Casper. In May 2026, they will present their long-term value creation policy at an investor event.

Danaher's Business Structure

An industrial conglomerate in the science, technology, and medical fields, with reporting segments divided into Biotechnology, Life Sciences, and Diagnostics. Established in 1969, headquartered in Washington D.C.

Main Business Areas

• Biotechnology — Technologies, consumables, and services that support the development and manufacturing of therapeutic drugs. Development services for cell lines and cell culture media, process liquids, buffers, etc. Bioprocessing is the core of this.

• Life Sciences — Equipment and reagents for research

• Diagnostics — Clinical equipment, consumables, software, and services for hospitals, clinics, and testing centers

Strengths

• Gross margin of 58.99%, operating margin of 22.00%. This is profitability that clearly surpasses Thermo Fisher.

• Danaher Business System (DBS): A mechanism for applying disciplined improvement methods to acquired companies to boost profit margins. It is the company's hallmark.

• A light financial structure with a D/E ratio of 0.37. It secures capital deployment optionality.

• A revenue structure centered on consumables. Continuous income follows after selling equipment.

• It continuously executes business streamlining, and in 2023, it spun off its water quality and product quality-related businesses as Veralto.

Challenges

• Core revenue growth is 3.0%, which lags behind Thermo Fisher's organic growth of 5%.

• The decline in respiratory testing is expected to be a headwind of approximately 2.5 percentage points in the third quarter.

• Bioprocessing revenue is easily influenced by the timing of customer projects, leading to greater volatility in quarterly performance.

• ROE of 7.08%, ROIC of 6.86%. This is a low level for a company with an operating margin of 22%.

• The stock price fluctuation over the last 52 weeks is approximately -2.16%, indicating that market valuation has not recovered.

Mid-term Policy: Operational improvement centered on DBS and portfolio expansion through M&A are the pillars. Acquisitions of Masimo and StatLab were completed in early 2026, and capital allocation is focused on M&A and strategic investments. The company has indicated an expectation to reach mid-single-digit core growth by the end of 2026, and the management team is led by President and CEO Rainer M. Blair.

④ Differences in the business strategies of the two companies

"Downstream" or "Upstream"?

The reason for the 18-point gap in gross margin between the two companies lies in the positioning of their business portfolios.

Thermo Fisher also holds the downstream. The Fisher Scientific sales channel, as well as CDMO (contract development and manufacturing organization) and clinical research services. While these are large in scale and boost sales, their profit margins are structurally low. The scale of over $45 billion in annual revenue is precisely because it holds these downstream businesses.

Danaher is focused on the upstream. Consumables essential for biopharmaceutical manufacturing, diagnostic equipment, and their reagents. It concentrates on products that are embedded in laboratories and production lines and are purchased repeatedly. Although its sales scale is about half that of Thermo Fisher, the gross profit extracted from $1 of sales is about 1.4 times higher.

How to "digest" acquisitions

Both companies have grown through acquisitions, and they even have names for their methods.

Thermo Fisher has the PPI Business System, and Danaher has the Danaher Business System (DBS). Both are mechanisms for applying common operational improvement methods to acquired companies to raise profit margins. This "ability to reshape acquired companies in their own style" is the reason why both companies have been able to repeat M&A for many years.

The difference lies in how they handle acquisitions. Danaher is proactive about spinning off businesses that are no longer needed, such as the separation of Veralto in 2023.Buy, fix, and divest what doesn't fit. Thermo Fisher is also moving in the same direction, proceeding with the sale of its microbiology business.

Capital Allocation Policy

This is where they contrast.

Danaher maintains a light balance sheet with a D/E ratio of 0.37, ensuring capacity for acquisitions. In fact, they acquired Masimo and StatLab in early 2026. Its dividend yield is 0.81%, exceeding Thermo Fisher's 0.33%.

Thermo Fisher uses leverage more aggressively, with a D/E ratio of 0.81. In the second quarter, it executed a $1 billion share buyback funded by the expected proceeds from the sale of its microbiology business.Agile capital allocation by immediately using the cash from divestitures for share buybacks.

Structural Differences Created by Strategy

Danaher's 'upstream focus + light balance sheet' approach has resulted in high profit margins and acquisition capacity. However, revenue is easily swayed by the timing of customer projects, leading to greater quarterly volatility. The recent bioprocessing situation was a classic example of this.

Thermo Fisher's 'breadth including downstream + leverage utilization' approach sacrifices some profit margin but provides demand diversification.Even if pharma/biotech is weak, academic/government and industrial sectors provide support. This structure leads to the stability of 5% organic growth.

⑤ Market Size (TAM) and Growth Potential

Regarding the Life Science Tools Market

Regarding the life science tools and diagnostics market, which is the main battlefield for both companies, we could not confirm reliable market size figures with consistent definitions within the scope of this article's research. This is because the scope of 'life science tools,' 'bioprocessing,' and 'in vitro diagnostics' varies significantly depending on the research firm. We will avoid citing estimates without sources and limit ourselves to a qualitative summary.

What Can Be Confirmed from Public Documents

• Thermo Fisher's annual revenue exceeds $45 billion, with a full-year 2026 outlook of $47.40 billion to $48.10 billion.

• Thermo Fisher's 2026 organic revenue growth outlook is approximately 4%.

• Danaher's 2026 non-GAAP core revenue growth outlook is 3.0–4.0%, or mid-single digits excluding respiratory testing.

• Danaher has indicated an expectation to reach mid-single-digit core growth by the end of 2026.

• In Thermo Fisher's second quarter, pharma/biotech grew in the mid-single digits, academic/government in the low-single digits, and industrial/applied in the mid-single digits.

How to Read Demand Structure

There are three major variables that drive this market.

The first is the R&D budget of pharmaceutical and biotechnology companies. This is the largest end market for both companies. Thermo Fisher explained that spending by biotechnology companies improved in the second quarter and that this has begun to translate into revenue. It can be read as a phase where demand is returning after several years of adjustment.

The second is academic and government budgets. Capital investment by universities and public research institutions is influenced by policy. Thermo Fisher's performance in this sector has remained at low single-digit growth, lacking strength.

The third is the normalization of diagnostic demand. The decline in respiratory testing that Danaher is facing is part of the process of shedding the special demand from the pandemic period. The company explained that after being a headwind of approximately 2.5 points in the third quarter, the comparison will ease in the fourth quarter.It is natural to understand this not as a deterioration of the business, but as a process of the clock returning to normal.

The market is not expanding rapidly. The reason why the growth outlook for both companies remains in the 3-5% range is that the cruising speed of the market itself is at that level. That is precisely why both companies have added to their growth rates through acquisitions.

⑥ Competitive Advantages and Barriers to Entry for Each Company

Barriers to entry common to this industry

First, let's organize the commonalities.

• Validation: In pharmaceutical manufacturing and clinical diagnostics, the equipment, reagents, and consumables used become part of the procedures registered with regulatory authorities.Switching to another manufacturer requires re-validation and regulatory compliance, and in practice, there are situations where it is almost impossible.

• Continuous demand for consumables: Once equipment is installed, the customer will continue to purchase dedicated reagents and consumables. The structure is similar to the relationship between a printer and ink.

• Service network: Since the damage caused by research or manufacturing coming to a halt is significant, the breadth of the maintenance and support system becomes a selection criterion.

Thermo Fisher Scientific's competitive advantage

• Having a purchasing window: Through Fisher Scientific, researchers can procure everything they need in one place. The dual position of being both an equipment manufacturer and a distributor is not easily imitated by others.

• Bundle of brands: Thermo Scientific, Applied Biosystems, Invitrogen, Gibco. Each holds a standard position in its respective field.

• PPI Business System: The mechanism for increasing the profitability of acquired companies enhances the success rate of M&A.

• Diversification of end markets: Four pillars: Pharma/Biotech, Academic/Government, Industrial/Applied, and Diagnostics/Healthcare.

Types of barriers to entry: Switching costs (validation) / Sales channels / Brand / Economies of scale.
Sustainability of barriers: Strong. In particular, the scale of purchasing channels cannot be built in the short term even with capital investment.

Danaher's competitive advantage

• Position in bioprocessing: They supply consumables that are incorporated into the manufacturing process of biopharmaceuticals.They are a supplier tied to pharmaceutical manufacturing approvals, and switching is extremely difficult.

• Gross margin of 58.99%: The ability to maintain this level is in itself proof of pricing power.

• Danaher Business System (DBS): A post-acquisition integration and improvement methodology refined over decades. It is a mechanism widely studied in the industrial sector.

• Installed base of diagnostics: Equipment installed in hospitals and testing centers generates continuous demand for reagents.

• Financial flexibility: D/E ratio of 0.37. It consistently maintains a state ready for the next acquisition.

Types of entry barriers: Switching costs (regulations/validation) / Consumables model / Technology and patents / M&A execution capability
Sustainability of barriers: Robust. The switching costs for bioprocessing are among the highest in this industry.

Which moat is deeper?

Danaher for the 'depth' of the moat, and Thermo Fisher for the 'breadth' is how the author organizes it.

The figure of 58.99% gross margin is direct evidence of the depth of the moat. It means they are able to push back even when asked for discounts. Holding a position in bioprocessing, which is tied to pharmaceutical manufacturing approvals, is effective.

On the other hand, while Thermo Fisher is inferior in depth, its purchasing channels, end markets, and product categories are all broad.Even if one area collapses, the whole does not waver. I believe the reason Thermo Fisher is growing stably while Danaher's stock price fell 14% due to the bioprocessing issue is largely due to this difference in breadth.

⑦ Business environment scenario for the next 3 years

Tailwind scenario

• The recovery of R&D budgets for pharmaceutical and biotechnology companies becomes full-scale, and the organic growth of both companies accelerates.

• The decline in respiratory testing has run its course, and Danaher's core growth rate recovers to the mid-single digits.

• The mid-10% growth in bioprocessing orders is sequentially recorded as revenue.

• Academic and government budgets expand, boosting equipment demand.

• Danaher's acquisition of Masimo generates synergies exceeding expectations.

• Thermo Fisher's portfolio replacement (divestiture of low-profit businesses and share buybacks) improves profit margins and per-share metrics.

• The weak yen continues, boosting the yen-denominated valuation for Japanese investors.

Base scenario

• Continued growth at the market's cruising speed of 3-5%

• Thermo Fisher achieved approximately 4% organic growth and 9-11% adjusted EPS growth, in line with full-year forecasts

• Danaher achieved 3-4% core growth, accelerating toward the mid-single digits by year-end

• Both companies continue their strategy of boosting growth rates through M&A

• Goodwill and intangible assets from acquisitions continue to accumulate, leading to a persistent gap between GAAP and adjusted earnings

• Valuation levels of low-20s forward P/E are generally being maintained

Headwind Scenarios

• R&D budgets for pharmaceuticals and biotechnology are constrained again, causing demand recovery to falter

• Demand for equipment declines due to cuts in academic and government budgets

• Delays in customer projects for bioprocessing become prolonged

• Acquisition prices soar, leading to lower investment returns

• Impairment charges become necessary for goodwill associated with past acquisitions

• Demand in key markets like China changes abruptly due to policy shifts

• The yen strengthens, causing the yen-denominated valuation to decrease for Japanese investors

8. Why I am slightly more interested in Thermo Fisher

Reason 1: Capital efficiency is about twice as high

ROE 13.52% vs. 7.08%, ROIC 8.84% vs. 6.86%. Thermo Fisher, which loses in profit margins, wins significantly in capital efficiency.

The reason lies in the balance sheet. The assets of companies that have made repeated acquisitions accumulate large amounts of 'goodwill' and intangible assets. While Danaher boasts high profit margins, the assets it holds to generate those profits (i.e., the amount paid for past acquisitions) are large. ROIC measures whether a return commensurate with the purchase price is being generated, and that is where the difference emerges.

Reason 2: All the numbers are pointing in the same direction

In the second quarter, organic growth was 5%, adjusted EPS grew 13%, adjusted operating margin improved by 90 basis points, it beat market expectations by $0.31, and full-year guidance was raised. There is not a single contradiction. I appreciate that there is no discrepancy like the one seen with Danaher, where 'earnings increased but the stock price plunged 14%'.

Reason 3: Diversification of demand is effective

Pharma/Biotech is in the mid-single digits, Academic/Government is in the low-single digits, and Industrial/Applied is in the mid-single digits. A structure where the whole does not collapse even if one part is weak is in place. This is in contrast to Danaher, which is facing a 1.5 to 2.5 percentage point headwind from the single factor of respiratory testing.

Counter-perspective and rebuttal points

I will also fairly present the arguments in favor of Danaher.

• Difference in profitability: Gross margin 58.99% vs. 40.91%, operating margin 22.00% vs. 18.98%. One could read this as Danaher having higher quality business operations as well.

• Financial lightness: D/E ratio 0.37 vs. 0.81, net interest-bearing debt $13.98 billion vs. $38.49 billion. They have the capacity to move on to the next acquisition.

• Undervalued on an enterprise value basis: EV/EBITDA 19.00x vs. 24.31x, EV/FCF 28.49x vs. 34.12x. When debt is taken into account, Danaher has a lower multiple.

• Stock price has already been sold off: Down approximately 2.16% over the last 52 weeks, and experienced a temporary 14.3% plunge after earnings. Expectations have been significantly lowered, and the starting point is different from Thermo Fisher's +21.76%.

• Transitory factors: The decline in bioprocessing revenue is due to the timing of customer projects, and orders are growing in the mid-10% range. The headwind from respiratory testing is also expected to ease in the fourth quarter.

• Dividends: At 0.81% vs. 0.33%, Danaher exceeds in terms of return levels.

• Risks on the Thermo Fisher side: EV/EBITDA 24.31x, D/E ratio 0.81. Both valuation levels and leverage are at higher positions than Danaher.

If you prioritize "capital efficiency and consistency of execution," choose Thermo Fisher; if you prioritize "high profitability and oversold levels," choose Danaher. Since the Fwd PER is almost the same, which logic you adopt will directly determine your decision.

9. Competitive map of both companies (6 companies)

Direct competitors

• Agilent Technologies (A/NYSE): A major player in analytical instruments, chromatography, and mass spectrometry. It competes head-on with Thermo Fisher's instrument business and shares customers in the life science research field.

• Revvity (RVTY/NYSE): The former life sciences and diagnostics division of PerkinElmer. It overlaps with both companies in the reagents and diagnostics fields.

Broad competitors

• Mettler-Toledo (MTD/NYSE): A global leader in precision weighing instruments and analytical instruments. It has a relationship of sharing laboratory equipment budgets.

• Waters (WAT/NYSE): Specializes in liquid chromatography and mass spectrometry. It holds a superior technical position in specific areas compared to both companies.

Overseas/Alternative Competitors

• Sartorius (Frankfurt Stock Exchange, Germany): A major European player in bioprocessing equipment and consumables. It competes most directly with Danaher's bioprocessing business, and in fact, its stock also fell following Danaher's earnings report.

• Illumina (ILMN/NASDAQ): A global leader in genetic analysis (sequencers). It competes with Thermo Fisher's genetic analysis business.

Looking at the competitive map, it becomes clear that competition in this industry is about 'staking out territory within the laboratory.' The customers (pharmaceutical companies and research institutions) are the same, and each company has its own turf in different processes. Thermo Fisher captures the surface area by controlling purchasing channels, while Danaher gains depth by embedding itself into the core of the manufacturing process. The fact that the stock prices of Sartorius and Bio-Rad moved following Danaher's earnings is evidence that this industry shares the same waves of demand.

⑩ Respective Risk Factors

Risks for Thermo Fisher Scientific

• Leverage: D/E ratio of 0.81, net interest-bearing debt of $38.49 billion. Debt has accumulated as a result of repeated acquisitions.

• Valuation Levels: EV/EBITDA of 24.31x, PEG ratio of 2.53. It is valued at a higher multiple than Danaher, leaving room for adjustment during periods of slowing growth.

• Low Gross Margin: 40.91%. Due to its structure, which includes sales channel businesses and CDMO, it is considered difficult to close the gap with Danaher.

• Academic and Government Demand: Growth remains in the low single digits, and this area is susceptible to policy changes.

• Goodwill Impairment Risk: Intangible assets have accumulated due to numerous acquisitions, and a re-evaluation will be necessary if the business environment deteriorates.

• Low Dividend Yield: 0.33%. This level is unlikely to provide support when the stock price is being sold off.

Risks for Danaher

• Low Core Growth Rate: 3.0% (4.5% excluding respiratory testing). This lags behind Thermo Fisher's organic growth of 5%.

• Headwinds in Respiratory Testing: Expected to intensify to approximately 2.5 percentage points in the third quarter.

• Volatility in Bioprocessing: Revenue is swayed by the timing of customer projects, making quarterly performance less predictable. This is also the direct cause of the recent sharp drop in the stock price.

• Capital Efficiency: ROE 7.08%, ROIC 6.86%. This is low for a company with an operating margin of 22.00%, raising the question of whether it is generating returns commensurate with past acquisition prices.

• Stock Price Volatility: The stock fell by as much as 14.3% the day after earnings, approaching its 52-week low of $160.93. This is reported to be the largest drop in decades.

• Acquisition Dependency: The structure relies on M&A to boost growth rates; if the number of deals decreases, the growth rate will converge to market levels.

• Integration Risk: There is a possibility that the integration of Masimo and StatLab may not proceed as planned.

Common Risks

• Cuts in R&D budgets of pharmaceutical and biotechnology companies

• Reductions in academic and government funding

• Policy changes and geopolitical risks in major markets, including China

• Lower investment yields due to soaring acquisition prices

• Impairment of goodwill and intangible assets

• Significant divergence between GAAP earnings and adjusted earnings, requiring caution when interpreting indicators

• For Japanese investors, exchange rate fluctuations directly affect yen-denominated gains and losses

⑪ Summary by Reader Interest Axis

Growth-Oriented Perspective

Second-quarter organic (core) growth was 5% for Thermo Fisher and 3.0% for Danaher (4.5% excluding respiratory testing). Full-year guidance is approximately 4% for Thermo Fisher and 3.0–4.0% for Danaher. Adjusted EPS growth is 13% vs. 8.0%.Thermo Fisher outperforms in all metrics. However, Danaher has indicated an expectation to reach mid-single-digit core growth rates by the end of the year, leaving room for recovery.

Stability-Oriented Perspective

The D/E ratio is 0.37 for Danaher and 0.81 for Thermo Fisher. The current ratio is 1.87 vs. 1.55.Danaher is clearly superior in financial health. On the other hand, in terms of business diversification, Thermo Fisher has more depth, creating a structure where the whole is less likely to be shaken by a single factor. Betas are 0.82 vs. 0.87, both lower than the market average, giving them a defensive character.

Dividend-Oriented Perspective

Dividend yields are approximately 0.81% for Danaher ($1.60/year) and approximately 0.33% for Thermo Fisher ($1.88/year).Danaher's level is about 2.5 times higher. However, the absolute levels for both companies are low, and these are not stocks to choose for income purposes. Both companies are reducing the number of outstanding shares through share buybacks (Thermo Fisher down 1.45%, Danaher down 2.27%), which is the primary focus of their shareholder returns.

A Value-Oriented Perspective

The Fwd PER is nearly identical at 21.66x vs. 21.62x. However, in terms of EV/EBITDA, it is 19.00x (Danaher) vs. 24.31x (Thermo Fisher), and for EV/FCF, it is 28.49x vs. 34.12x, meaning Danaher has a lower multiple on an enterprise value basis including debt. Additionally, Danaher's stock price has not grown over the last 52 weeks, down approximately ▲2.16％, and is in a recovery phase from its 52-week low. Looking at the metrics alone, Danaher has the advantage.

⑫ The intrigue of this comparison

Microscopes, reagents, and petri dishes are not drugs in themselves. However, without them, drugs cannot be created. The business of "selling science itself" has created two such massive companies — that is the starting point of this pair.

And neither company grew on its own. They have repeatedly made acquisitions over decades, and each time, they have reshaped the acquired companies in their own image. Thermo Fisher's PPI Business System, Danaher's Danaher Business System. They have named and refined their methods to the point where "improving acquired companies" has become their core business.

The core of Thermo Fisher is that it has "secured the point of contact." It possesses the Fisher Scientific purchasing platform, delivering everything a researcher needs in one go. Therefore, its gross margin is diluted to the 40% range, but sales exceed $45 billion, and demand is diversified across four end markets.

The core of Danaher is that it is "embedded in the process." It supplies consumables tied to biopharmaceutical manufacturing approvals. Because the only way to switch is to redo the regulatory approval process, they are not pressured to offer discounts. Therefore, a gross margin of 58.99% is sustainable. In exchange, their performance fluctuates if a customer's project is delayed by even one quarter. The recent 14% plunge was the flip side of that.

And most interestingly, there is a reversal where Danaher, which wins on profit margins, loses on capital efficiency. ROE is 7.08% vs. 13.52%. What creates this difference is the "goodwill" accumulated on the balance sheet—the amount paid for past acquisitions.

"A good business" and "a good investment" are different. The textbook example of this is the contrast between these two companies.

Record Data

• Record Date: July 28, 2026

• Exchange Rate: 1 USD = 163.6 JPY (Based on the July 24, 2026 New York market closing price)

• Thermo Fisher Scientific (TMO/NYSE): Stock price approx. $568.27 (as of July 24, 2026, calculated value), market capitalization approx. $211.18 billion, PER (trailing) approx. 30.58x, Fwd PER approx. 21.66x, dividend yield approx. 0.33%, ROE 13.52%, ROIC 8.84%, beta 0.87, fiscal year-end December

• Danaher (DHR/NYSE): Stock price $196.50 (July 27, 2026 closing price), market capitalization approx. $138.14 billion, PER (trailing) approx. 34.11x, Fwd PER approx. 21.62x, dividend yield approx. 0.81%, ROE 7.08%, ROIC 6.86%, beta 0.82, fiscal year-end December

• Latest earnings announcement: Danaher July 21, 2026 / Thermo Fisher Scientific July 23, 2026 (both Q2)

Sources of Numerical Data

• Thermo Fisher Scientific "Thermo Fisher Scientific Reports Second Quarter 2026 Results" (July 23, 2026) and SEC Form 8-K, earnings presentation

• Danaher "Danaher Reports Second Quarter 2026 Results" (July 21, 2026), earnings presentation and explanatory materials

• StockAnalysis.com (Stock price, market cap, PER, financial ratios. Danaher as of July 27, 2026 closing price, Thermo Fisher Scientific as of July 24, 2026)

• Google Finance, Reuters, Barron's, TipRanks (stock price fluctuations and market reaction)

• Exchange rates are based on market reports from Fisco, OANDA, etc., as of July 24, 2026.

• The stock price of Thermo Fisher Scientific is a calculated value derived by dividing the market capitalization by the number of shares outstanding.

Read also

• Thermo Fisher Scientific vs. Illumina — A Thorough Comparison of Business Growth Potential

• Veralto vs. Xylem — A Thorough Comparison of Business Growth Potential

Request

If you found this article helpful, please consider liking and following, as it encourages me. If there are any stock combinations you would like me to cover, please let me know in the comments.

Important Matters (Disclaimer)

This article does not solicit the purchase or sale of any specific stock, nor does it constitute investment advice. The information provided is organized by the author based on publicly available materials and does not guarantee its accuracy or completeness. Numerical values are as of the time of recording and may fluctuate thereafter. Please note that there is a one-business-day difference in the stock price acquisition dates for both companies in this article, and that the stock price for Thermo Fisher Scientific is a calculated value. Since figures for both companies differ significantly between GAAP and non-GAAP (adjusted) metrics, it is necessary to confirm the basis of comparison. Danaher's stock price has fluctuated significantly following its earnings announcement on July 21, 2026, and the stated stock price levels may change in a short period. Investing in U.S. stocks involves foreign exchange risk and tax treatments that differ from those for Japanese stocks. Please make final investment decisions at your own responsibility.

Bonus: Today's Terminology Explained

What is 'Goodwill'?

When acquiring a company, it is the amount paid in excess of the target's net asset value.

For example, suppose you buy a company with 5 billion yen in net assets for 15 billion yen. What was the extra 10 billion yen paid for? It is for value not recorded on the balance sheet—such as brand, engineers, customer relationships, and future earning power. This 10 billion yen is recorded as 'goodwill' on the buyer's assets.

Both Thermo Fisher and Danaher have repeatedly made acquisitions over several decades. Therefore, on both companies' balance sheets, huge amounts of goodwill and intangible assets have accumulated.

This is an important point. Since goodwill is an asset, it inflates the denominator of ROE (Return on Equity) and ROIC (Return on Invested Capital). In other words, 'the more expensive a company was bought, the lower its subsequent return rate appears.' The fact that Danaher has an ROE of only 7.08% despite its high profitability with an operating margin of 22% is largely due to this structure.

And one more thing. If it is determined that the value of an acquired business has declined, the goodwill is written off as an impairment loss all at once. When looking at companies that have grown through acquisitions, if you are conscious of not just 'what was bought' but also 'how much it was bought for,' the meaning of the numbers will start to look different.